Latest Headlines

  1. Hinge Bio Announces FDA Clearance Of Investigational New Drug Application For HB2198, A Novel B Cell-Depleting Agent, For Patients With Systemic Lupus Erythematosus And Lupus Nephritis 10/13/2025

    Hinge Bio, Inc., a privately-held biotechnology company engaged in the discovery and development of innovative multi-specific medicines, announced the U.S. Food and Drug Administration (“FDA”) has cleared the company’s Investigational New Drug (“IND”) application to initiate a study of HB2198 in patients with the B cell-mediated autoimmune diseases Systemic Lupus Erythematosus (“SLE”) and Lupus Nephritis (“LN”).

  2. Chance Pharma Announces Commercialization Agreement With Huadong Medicine For Innovative Respiratory Drug CXG87 10/9/2025

    Chance Pharmaceuticals ("Chance" or "Chance Pharma"), a clinical-stage biotechnology company dedicated to the research and development of innovative inhalation therapies, today announced that it has reached an exclusive commercialization agreement with Huadong Medicine (Hangzhou) Co., Ltd., a wholly owned subsidiary of Huadong Medicine Co., Ltd. (000963.SZ, "Huadong Medicine"), to commercialize CXG87 in Mainland China.

  3. Macomics Announces Neurodegeneration And Neuroinflammation Applications Of ENIGMAC Drug Discovery Platform 10/8/2025

    Macomics Ltd, a leader in macrophage drug discovery, announces that it has validated its ENIGMAC™ platform in neurodegeneration and neuroinflammation applications.

  4. Immuron Submits IMM-529 IND To FDA 10/8/2025

    Immuron Limited (ASX: IMC; NASDAQ: IMRN), is pleased to announce that it has submitted an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) for clinical development of IMM-529.

  5. Sai Life Sciences, Agility Life Sciences, And Centrix Pharma Solutions Announce An 'Integrated CMC Partnership' To Accelerate Drug Development For Innovators 10/8/2025

    Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), Agility Life Sciences, and Centrix Pharma Solutions today announced the launch of an Integrated CMC Partnership designed to provide innovator biopharma companies with end-to-end Chemistry, Manufacturing and Controls (CMC) services.

  6. BenchSci Announces Three-Year License Agreement With Sanofi To Access And Use BenchSci's ASCEND Platform 10/8/2025

    BenchSci, a world leader in AI solutions for preclinical research and drug discovery, today announced a three-year agreement with Sanofi to deploy and use BenchSci’s ASCEND platform across Sanofi’s global preclinical research organization.

  7. Collaborations Pharmaceuticals, Inc., Partners With Bausch + Lomb To Publish Research On Advancing AI Drug Development 10/7/2025

    Collaborations Pharmaceuticals, Inc. (CPI) has partnered with Bausch + Lomb to build and validate an array of artificial intelligence (AI) machine learning models with the goal of identifying new oral drugs that could reach the eye. 

  8. New Drug Combination Offers Hope For Men With Advanced Prostate Cancer 10/7/2025

    A new drug combination could significantly delay the progression of a life-threatening form of prostate cancer in men with specific genetic mutations, finds a major international trial led by UCL researchers.

  9. MOLCURE Joins Forces With Boehringer Ingelheim To Discover And Develop Innovative Antibody Drugs For Multiple Targets Using Its AI-Driven Platform Technology 10/7/2025
  10. Precision NeuroMed Granted FDA Orphan Drug Designation By U.S. FDA For Treatment Of Glioblastoma Multiforme (GBM) 10/7/2025

    Precision NeuroMed (PNM), a clinical-stage biotechnology company pioneering advanced drug delivery technologies for central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its investigational therapy for glioblastoma (GBM).